Announcement • Jan 06
ProPhase Labs, Inc. (NasdaqCM:PRPH) acquired World-wide exclusive rights to Stella’s BE-Smart Esophageal Pre-Cancer diagnostic screening test from Stella Diagnostics Inc. (OTCPK:SLDX) for $4.6 million. ProPhase Labs, Inc. (NasdaqCM:PRPH) entered into an asset purchase agreement to acquire World-wide exclusive rights to Stella’s BE-Smart Esophageal Pre-Cancer diagnostic screening test from Stella Diagnostics Inc. (OTCPK:SLDX) for $4.5 million on December 19, 2022. As consideration for the Purchased Assets, ProPhase Labs, Inc. will (i) pay to the Stella Diagnostics Inc. $3.486 million in cash, minus (a) the Secured Note Amount, if any, (b) the Liability Payoff Amount and (c) the Promissory Note Payoff Amounts and (ii) issue to Stella DX 0.1 million shares of common stock, par value $0.0005 per share, of ProPhase Labs, Inc. Under the terms of the agreement, an additional $2 million of ProPhase Labs common stock may be issued to Stella in the future upon the achievement of a revenue-based commercial milestone within the five-year period following the closing. The transaction is subject to customary closing conditions, including the receipt of all required approvals, consents and waivers, including the requisite approval by the stockholders of Stella and is expected to close in early January 2023. ThinkEquity acted as advisor to ProPhase Labs in the transaction. Reed Smith LLP acted as legal advisor to ProPhase Labs. Thompson Hine LLP acted as legal advisor to Stella Diagnostics in the transaction.
ProPhase Labs, Inc. (NasdaqCM:PRPH) acquired World-wide exclusive rights to Stella’s BE-Smart Esophageal Pre-Cancer diagnostic screening test from Stella Diagnostics Inc. (OTCPK:SLDX) for $4.6 million on January 5, 2023. Announcement • Dec 21
ProPhase Labs, Inc. (NasdaqCM:PRPH) entered into an asset purchase agreement to acquire World-wide exclusive rights to Stella’s BE-Smart Esophageal Pre-Cancer diagnostic screening test from Stella Diagnostics Inc. (OTCPK:SLDX) for approximately $4.5 million. ProPhase Labs, Inc. (NasdaqCM:PRPH) entered into an asset purchase agreement to acquire World-wide exclusive rights to Stella’s BE-Smart Esophageal Pre-Cancer diagnostic screening test from Stella Diagnostics Inc. (OTCPK:SLDX) for approximately $4.5 million on December 19, 2022. The purchase price comprised of approximately $3.5 million in cash and $1 million in ProPhase common stock. Under the terms of the agreement, an additional $2 million of Company common stock may be issued to Stella in the future upon the achievement of a revenue-based commercial milestone within the five-year period following the closing. The transaction is subject to approval by Stella shareholders and is expected to close in early January 2023. ThinkEquity acted as advisor to ProPhase Labs in the transaction. Announcement • Apr 23
Stella Diagnostics Inc. Appointment of Joe Abdo as Chief Scientific Officer Stella Diagnostics Inc. announced leadership changes in conjunction with the next phase of its business plan. In order to successfully implement new processes, products, and business strategies, Dr. Joe Abdo will assume the newly created position of Chief Scientific Officer, and David Seaburg, who is currently a member of Stella Diagnostics’ Board of Directors, has been appointed Chief Executive Officer. The planned leadership transition reflects Stella Diagnostics’ Board of Directors succession planning process. Accordingly, the Board conducted a comprehensive evaluation of internal and external candidates. Following a thorough assessment, the Board unanimously determined the leadership changes. Dr. Joe Abdo has over a decade of experience in molecular oncology research, as well as business development in both private and public biotechnology organizations. Dr. Joe Abdo has over a decade of experience in molecular oncology research, as well as business development in both private and public biotechnology organizations. 
